Islet Cell Transplantation The Oxford AHSN Diabetes Clinical Network Launch Event, February 2014

Similar documents
NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE PANCREAS ADVISORY GROUP AUDIT OF STANDARD CRITERIA FOR LISTING SUMMARY

Islet and Pancreas Transplantation

Eilandjes transplantatie. Eelco de Koning, LUMC 14 februari 2008

The number of patients waiting on the pancreas transplant list fell by 1% during the year, to 224 at 31 March 2017

THE BIOARTIFICIAL PANCREAS

The number of patients waiting on the pancreas transplant list fell by 7% during the year, to 252 at 31 March 2015

A03/S(NHSS)c NHS STANDARD CONTRACT FOR ISLET TRANSPLANTATION SERVICE (ADULT) SERVICE SPECIFICATIONS. Service Specification No.

Islet cell transplantation: current status in the UK

Clinical Policy: Pancreas Transplantation Reference Number: PA.CP.MP.102

Pancreas Transplantation. Sonia Clarke-Swaby Recipient Kidney/pancreas Transplant Co-ordinator Guy s Hospital

Clinical impact of de-novo HLA antibodies in pancreas and islet transplantation

Monitoring in Type 2 Diabetes. Learning Outcomes. Type 2 Diabetes. Senga Hunter Community Diabetes Specialist Nurse

NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system

Transplanting donated pancreatic islet cells for patients with type 1 diabetes

PARTICULARS, SCHEDULE 2 THE SERVICES, A SERVICE SPECIFICATION. A03/S(HSS)/a Pancreas transplantation service (Adult)

Improving Diabetes Care The role of the integrated diabetes network. Ian Gallen Royal Berkshire Hospital

Chapter 4 Section Simultaneous Pancreas-Kidney (SPK), Pancreas-After-Kidney (PAK), And Pancreas-Transplant-Alone (PTA)

Integrated Community Diabetes Services (ICDS) GP Referral Guide Version 3 - October 2014

Chapter 4 Section 24.7

[Frida Svendsen and Jennifer Southern] University of Oxford

SURGICAL CURES FOR DIABETES

Summary of Significant Changes. Policy

Pancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP

Audit support for continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57)

β-cell Preservation and Regeneration After Islet Transplantation

Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

Insulin Optimisation Workshop. Theingi Aung & Claire Rowell

Placename CCG. Policies for the Commissioning of Healthcare

hypoglycaemia unawareness keystone 18 July 2014

Policy for the Provision of Continuous Glucose Monitoring and Flash Glucose Monitoring to patients with Diabetes Mellitus

Australia & New Zealand Pancreas. Transplant Registry Report

Manchester Royal Infirmary Renal & Pancreas Transplant Unit / 2012 Activity Annual Report

CHAPTER 3 SECTION 1.6G SIMULTANEOUS PANCREAS-KIDNEY, PANCREAS-AFTER-KIDNEY, AND PANCREAS-TRANSPLANT-ALONE

Referral to Adult Diabetes Specialist Services

Corporate Medical Policy

Transplant Activity in the UK

ANNUAL REPORT ON PANCREAS AND ISLET TRANSPLANTATION

The National DAFNE Audit

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) JAPC Briefing FreeStyle Libre

Potential Vision for Diabetes Care

Pancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry

Future Therapies in the Treatment of Diabetes: Islet Transplantation

What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital

Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes

Diabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust

Allogeneic Pancreas Transplant

Preoperative tests (update)

Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes

Allogeneic Pancreas Transplant

MANAGING MEALTIME INSULIN

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

Islet Transplantation

THE SHEFFIELD AREA PRESCRIBING GROUP. Position Statement for Prescribing of Freestyle Libre In Type 1 Diabetes. Date: March 2018.

José Oberholzer, MD. Director Charles O. Strickler Transplant Center. Chief, Division of Transplantation

Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico

The most recent estimates suggest that. A study of inpatient diabetes care on medical wards. Saqib Javed, Yaser Javed, Kate Barnabas, Kalpana Kaushal

Islet Cell Allo-Transplantation. Disclosure. Objectives

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)

Managing Problematic Hypoglycaemia Pratik Choudary

Insulin Management. By Susan Henry Diabetes Specialist Nurse

Who Should Be Considered for Islet Transplantation Alone?

Islet Transplantation. Description

Hot Topics in Diabetic Kidney Disease a primary care perspective

Allogeneic Pancreas Transplant. Description

Summary of Significant Changes. Policy

In keeping with the Scottish Diabetes Group criteria, use should be restricted to those who:

Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Islet Transplantation

Therapeutic Apheresis Services Annual Review 2016/17

Guideline for antihyperglycaemic therapy in adults with type 2 diabetes

Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus

What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?

Insulin pumps. Norman Waugh Warwick Medical School.

Australia & New Zealand Pancreas. Transplant Registry Report Inquiries or comments should be directed to the secretariat at:

University College Hospital. Blood glucose and HbA 1 c targets

EAST OF ENGLAND CHILDREN AND YOUNG PEOPLE S DIABETES NETWORK. Optimising Glycaemic Control for Children and Young People with Diabetes

Diabetic nephropathy and -cell replacement therapy

National Diabetes Insulin Pump Audit, England and Wales

TRANSPLANT ACTIVITY IN THE UK

Small bowel and Multivisceral Transplantation

UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1

For more information about how to cite these materials visit

Manchester Royal Infirmary Renal & Pancreas Transplant Unit / 2011 Activity Annual Report

Tenth Annual Report. Prepared by: CITR Coordinating Center The Emmes Corporation Rockville, MD

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre

NHS Leeds CCG. Policy for the Funding of Flash Glucose Monitoring (FlashGM) in Paediatrics and Adults

ANNUAL REPORT ON PANCREAS AND ISLET TRANSPLANTATION

Dr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

Introducing. 15 th October, 2013 Oxford Centre for Diabetes, Endocrinology and Metabolism

Scientific Summary of the Collaborative Islet Transplant Registry (CITR) 2013 (Ninth) Annual Report

UEMS & EBS: DIVISION OF TRANSPLANT SURGERY

MEDICAL POLICY. POLICY NUMBER: CATEGORY: Transplants

Vascular Remodelling in Pancreas Transplantation

Original Policy Date

National Diabetes Transition Audit, England and Wales

Allogeneic Pancreas Transplant. Populations Interventions Comparators Outcomes Individuals: With insulin-dependent diabetes

Transcription:

Islet Cell Transplantation The Oxford AHSN Diabetes Clinical Network Launch Event, February 2014 Stephen Gough

Islet Transplant Service (Oxford)

Islet v Pancreas Two different approaches

Ideal Traetmanet fo What are the options available? IDDM Whole Pancreas Transplantation - Simultaneous pancreas + kidney (SPK) - Pancreas Transplant Alone (PTA) - Pancreas after kidney (PAK) Islet Transplantation - Islet Transplant Alone (ITA) - Islet after kidney (IAK) - Simultaneous islet + kidney (SIK) - Autotransplantation

History of islet cell transplantation 267 allografts, 1990-2000 41% some graft function 12.4% insulin-independence >1 week 8.2% insulin-independence for >1year

Islet Transplantation in Oxford Pre-NHS up to 2008 9 Transplants pre-edmonton Protocol 3 Transplants post-edmonton Protocol (funded by DUK) NHS post 2008 Currently 8-10 per annum (~30-40 Across UK) April 2013 present, 7 (2+5)

National NHS Consortium Oxford Kings (Edinburgh) Newcastle Manchester Royal Free (Bristol)

Islet cell transplantation: why? To improve the quality of life of people with T1DM who suffer severe, recurrent and potentially life-threatening hypoglycaemia To improve hypoglycaemia unawareness? to achieve insulin-independence

Transplantation inclusion criteria T1DM, > 18 years of age, > 5 years duration Failure to optimise glycaemic control with standard therapy without hypoglycaemia Impaired awareness of hypoglycaemia Recurrent severe hypoglycaemia, (2 or more episodes within the last 2 years)

Process Referral by diabetologist to transplant team to Oxford Centre Detailed clinical assessment including exclusion of other causes of hypo Discuss/council - risks/benefits/alternatives

The Islet Transplant Percutaneous transhepatic approach via portal vein, local anaesthetic Infuse over 10-15 minutes 12 hours bed rest Home 48-72 hours

Intensive Follow-up Metabolic control (Blood glucose 4-6 mmol) Immunosuppression (+infection/neoplasia) Assessment of graft function General medical review

Pancreas transplants Pancreatic islet transplant activity by centre (1 April 2008-8 January 2012) Routine Priority 40 35 34 30 25 20 15 10 5 0 16 9 10 6 4 3 3 4 4 3 1 2 1 Newc RF King's Oxf Manc Edin UK Transplant centre

Annual hypo rate Hypoglycaemia outcomes (snap shot of few patients 2008 2011) Impact of islet transplantation on annual hypo rate 70 60 50 40 30 20 10 0 Annual hypos pre Annual hypos post (UK 1 year graft survival >85%*) * Brooks AMSA Diabetic Med 2012; 29 (suppl1) :A15

International Outcome Data

Islet cell transplant outcomes Insulin independence Absence of severe hypoglycaemia 1 year 3 year 5 year 50% 35% 25% 90% 75% 50% (graft function >0.3ng/ml, 50-80% at 5 years)

Brookes AM et al

Severe hypoglycaemic event / patient / year Glycated haemaglobin (HbA1c %) Post-Islet Transplant Metabolic Outcomes 50 45 40 Annual hypos post Annual hypos pre 10 9.5 9 HbA1c post HbA1c pre 35 30 25 20 *p < 0.01 versus pre-transplant 8.5 8 7.5 7 8.23 * *p < 0.01 versus pre-transplant 15 10 5 0 23 Pre-transplant 0.56 * Post-transplant 6.5 6 5.5 5 Pre-transplant 6.83 Post-transplant Brookes AM et al. Am J Transplant 2013; 13: 3236-43

One witness who saw the defendant behind the wheel shortly before the accident described him as "looking paranoid His vehicle mounted a pavement, struck the boy and his brother, then went through a garden wall, across a garden and into a house in Stirchley. Leading up to the accident the defendant, who was at the wheel of a Renault, had been driving in an erratic manner and was seen to swerve across lanes...

Pre-transplant glucose profile (September 2009) HbA1c 7.0%

Post-transplant glucose profile HbA1c 6.0%

Glucometer trends May June 2012

January 2014 1 st transplant September 2009 Remains off insulin, on Liraglutide 1.2 mg OD

Challenges National funding for 100 per year Oxford largest centre 8-10 per year Most referrals from 2-3 centres Post-transplant follow-up, intensive Have 1 satellite clinic (Birmingham)

Proposal Increase hub and spoke service across TV AHSN funded transplant coordinator Satellite clinics Use of IT, (? Skype follow up in local centre)

Conclusions Islet cell transplantation Research to Clinical (NHS) service NICE Outcome Measures are being achieved Prevention of recurrent severe hypoglycaemia Attainment of HbA1c <53 mmol/mol (7%) Need to expand the service

Oxford Clinical Team Rob Crookston Chitra Ballav Paul Johnson Transplant Surgeons/Team Diabetes on-call team SpRs Islet Isolation Team Acknowledgements